Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > October 29, 2020
Daily News
October 29, 2020
- Japan to Receive 50 Million Doses of Moderna COVID-19 Vaccines via Takeda
October 29, 2020
- GSK Might Adjust Shipments for Cervarix as Surge in Demand Expected
October 29, 2020
- Sumitomo Dainippon’s Japan Sales Activities Hit by COVID-19, Virtual Calls Strengthened: President
October 29, 2020
- PhRMA Makes 3-Pronged Proposal to Japan Govt, Calls for Fueling Innovation, Investment, and Digitalization
October 29, 2020
- Sumitomo Dainippon’s Half-Year Sales Up 13.4% on Latuda Growth
October 29, 2020
- Chuikyo Reps Agree on Need to Validate Current Cost-Effectiveness Analysis Scheme
October 29, 2020
- Pharmaceutical Development Council Holds 1st Meeting; Aiming to Sort Out Priority Issues by March
October 29, 2020
- Santen Gets Asian Rights to Aerie’s Glaucoma Meds
October 29, 2020
- Enhertu Earns FDA’s Priority Tag for Gastric Cancer, Decision Due in Q1 2021
October 29, 2020
- AbbVie’s JAK Inhibitor Rinvoq Filed for Atopic Dermatitis in Japan
October 29, 2020
- Eisai Launches JV in China to Forge Health Service Platform for Elderly
October 29, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…